These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 20036108

  • 1. Variable daptomycin susceptibility in patients receiving intravenous vancomycin for meticillin-resistant Staphylococcus aureus infections.
    Golden M, Shaib W, Havill N.
    Int J Antimicrob Agents; 2010 Mar; 35(3):306-8. PubMed ID: 20036108
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.
    Jacobson LM, Milstone AM, Zenilman J, Carroll KC, Arav-Boger R.
    Pediatr Infect Dis J; 2009 May; 28(5):445-7. PubMed ID: 19295462
    [Abstract] [Full Text] [Related]

  • 4. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW, Murray CK, Holmes RL, Patterson JE, Jorgensen JH.
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Glycopeptide and daptomycin susceptibility and vancomycin heteroresistance of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates from a Greek university hospital.
    Panagea T, Galani I, Souli M, Karantani I, Giamarellou H, Petrikkos G.
    Int J Antimicrob Agents; 2011 Nov; 38(5):451-2. PubMed ID: 21840688
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
    Murray KP, Zhao JJ, Davis SL, Kullar R, Kaye KS, Lephart P, Rybak MJ.
    Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
    [Abstract] [Full Text] [Related]

  • 12. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin.
    Smith K, Perez A, Ramage G, Gemmell CG, Lang S.
    Int J Antimicrob Agents; 2009 Apr; 33(4):374-8. PubMed ID: 19101124
    [Abstract] [Full Text] [Related]

  • 13. Vancomycin, unbeatable for methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia? Really?
    Luna CM, Bruno D, Aruj P.
    Crit Care Med; 2010 Sep; 38(9):1910-2. PubMed ID: 20724890
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
    Parra-Ruiz J, Tomas-Jiménez C, Muñoz-Medina L, Hernández-Quero J.
    Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):372-3. PubMed ID: 19339080
    [No Abstract] [Full Text] [Related]

  • 16. Comparing antimicrobial susceptibility of meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin using MicroScan (Pos Combo 3.1J) and conventional methods.
    Nakashima H, Kameko M, Takahashi H, Saito H.
    Int J Antimicrob Agents; 2010 Sep; 36(3):291-3. PubMed ID: 20594808
    [No Abstract] [Full Text] [Related]

  • 17. Can clinical and molecular epidemiologic parameters guide empiric treatment with vancomycin for methicillin-resistant Staphylococcus aureus infections?
    Yamaki J, Lee M, Shriner KA, Wong-Beringer A.
    Diagn Microbiol Infect Dis; 2011 May; 70(1):124-30. PubMed ID: 21392923
    [Abstract] [Full Text] [Related]

  • 18. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG, Gao W, Ward PB, Howden BP.
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.